key: cord-0902743-0cefc4i2
authors: Kerget, Buğra; Kerget, Ferhan; Aydın, Murat; Karaşahin, Ömer
title: Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19
date: 2022-01-04
journal: J Med Virol
DOI: 10.1002/jmv.27552
sha: c5a8b53b232cbccd28d52650234a1d4e9b412c4a
doc_id: 902743
cord_uid: 0cefc4i2

The inflammatory/anti‐inflammatory balance has an important role in the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (coronavirus disease [COVID‐19]) infection, which has affected over 200 million people since it first appeared in China in December 2019. This study aimed to determine the effectiveness of montelukast, which has known anti‐inflammatory and bronchodilatory effects, in these patients. The prospective randomized controlled study included 180 patients who were hospitalized in the infectious diseases department of our hospital between May and July 2021 and were diagnosed with the delta variant of SARS‐CoV‐2 by real‐time polymerase chain reaction of nasopharyngeal swabs. The patients were divided into three groups and received only standard treatment according to national guidelines (Group 1) or standard treatment plus 10 mg/day montelukast (Group 2) or 20 mg/day montelukast (Group 3). Laboratory parameters and pulmonary function tests (PFTs) at admission and on Day 5 of treatment were compared. Comparison of laboratory parameters on Day 5 showed that Groups 2 and 3 had significantly lower levels of lactate dehydrogenase, fibrinogen, D‐dimer, C‐reactive protein, and procalcitonin compared with Group 1 (p = 0.04, 0.002, 0.05, 0.03, and 0.04, respectively). In the comparison between Groups 2 and 3, only fibrinogen was significantly lower in Group 3 (p = 0.02). PFT results did not differ between the groups at admission, while on Day 5, only Group 3 showed significant improvements in forced expiratory volume in 1 s, forced vital capacity, and peak expiratory flow 25–75 compared with admission (p = 0.001 for all). Montelukast may be beneficial in COVID‐19 patients to maintain the inflammatory/anti‐inflammatory balance, prevent respiratory failure through its bronchodilator activity, and reduce mortality.

Acute respiratory distress syndrome (ARDS) and macrophage activation syndrome (MAS) are among the main causes of morbidity and mortality in COVID-19. A contributing factor in the development of these clinical conditions is the overproduction of proinflammatory cytokines, primarily tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, and IL-1β. These cytokines cause increased leukocyte accumulation in the alveolar spaces and consequently an increase in reactive oxygen radicals and proteases, which inevitably leads to capillary endothelial damage and alveolar epithelial damage. 2, 3 Montelukast is a potent cysteinyl leukotriene (cysLT) receptor antagonist with anti-inflammatory activity and has been proven to significantly suppress oxidative stress. Moreover, cysLTs also have an important role in the regulation of cytokine production. Administration of high doses of montelukast reduces IL-4, IL-5, and IL-13 production by T-helper 2 cells. 4 This effect makes it an important anti-inflammatory agent in the treatment of asthma. In addition, montelukast was shown to significantly inhibit bradykinin-induced tracheal smooth muscle contraction, thus supporting an interaction between bradykinin and leukotriene mediators. 5 In studies investigating the efficacy of cysLT for ARDS and MAS, montelukast was found to increase interferon-γ (IFN-γ) production and significantly decrease the production of proinflammatory cytokines such as IL-1β, IL-6, and IL-8 in mice infected with a respiratory syncytial virus.

In another study, cysLT prevented neutrophil infiltration, lung inflammation, and oxidative stress and significantly decreased levels of TNF-α and IL-6 in both the lung parenchyma and bronchoalveolar lavage fluid in an animal model of ARDS induced by hemorrhagic shock.

In this study, we aimed to investigate the effect of treatment with varying doses of montelukast as an adjunct to standard antiviral therapy on pulmonary function tests and clinical courses in patients with COVID-19.

This prospective, randomized, controlled, single-blinded study included 180 participants who were divided into three groups: Group 1 (n = 60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide, Group 2 (n = 60) received 10 mg/day oral montelukast in addition to standard treatment, and Group 3 (n = 60) received 20 mg/day oral montelukast in addition to standard treatment ( Figure 1 ).

As the primary outcome of the study, we evaluated the effect of treatment on progression to ARDS and MAS during follow-up.

Secondary outcomes were the effects of treatment on lung capacity in pulmonary function testing. In addition, the patients' hematological parameters, biochemical parameters including liver and kidney function tests, coagulation parameters, ferritin, D-dimer, troponin-I, and C-reactive protein (CRP) levels were evaluated daily starting from the day of admission. Pulmonary function tests were performed at admission and repeated on Day 5 of treatment.

Based on the primary endpoint of the study, which was a 20% or greater reduction in the number of patients with clinical deterioration requiring admission to intensive care due to ARDS or MAS, we determined that 180 patients (60 in each group) were needed (α = 0.05, power = 95%, δ = −0.20).

Participants for this single-center study were recruited from among patients hospitalized in the infectious diseases ward of Erzurum Regional Training and Research Hospital, which has been designated as a pandemic hospital in the city for approximately 2 years.

Before starting the study, approval was obtained from the Atatürk University Faculty of Medicine Clinical Studies Ethics Committee.

The trial was registered on the ClinicalTrials. gov website with the official title "Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19" (identifier code: NCT05094596).

During the study period, patients who presented to the emergency department of Erzurum Regional Training and Research Hospital with a history of travel abroad within the last 14 days or contact with a confirmed or suspected COVID-19 patient and had recent complaints of fever, cough, dyspnea, malaise, and sudden loss of taste and smell were evaluated for COVID-19. Patients regarded as high risk for COVID-19 underwent standard high-resolution computed tomography (HRCT).

Predominantly peripheral bilateral ground-glass opacities, subsegmental consolidation or linear opacities, crazy-paving pattern, and reverse halo sign were considered typical HRCT findings for COVID-19. Patients with these findings and patients with radiologically atypical findings but Patients with any potential contraindications to pulmonary function testing (recent myocardial infarction, pulmonary embolism, cerebral aneurysm, active hemoptysis, pneumothorax, nausea/vomiting, recent thoracic, abdominal, or ocular surgery) were excluded before testing. In addition, patients who developed ARDS or MAS associated with secondary bacterial infection during the first week of treatment were also excluded.

Fever was defined as an axillary temperature of 37.3°C or higher.

Secondary bacterial infection was diagnosed based on signs and symptoms of bacteremia or pneumonia with the identification of a new bacterial pathogen in endotracheal aspirate or lower respiratory tract sputum culture. Treatment for patients diagnosed as having ventilator-associated or hospital-acquired pneumonia was planned according to available guidelines. Acute respiratory distress was diagnosed and graded according to the 2015 Berlin diagnostic criteria.

Patients with daily cardiac-specific troponin levels above the normal range underwent echocardiographic evaluation for new cardiac pathologies. Coagulopathy was defined as prothrombin time 3 s longer than normal and activated partial thromboplastin time 5 s longer than normal. If an adequate response was not observed, treatment was repeated at the same dose.

Patients in Group 1 were treated in accordance with the COVID-19 adult diagnosis and treatment guidelines issued by the Turkish Ministry of Health as specified above. Patients in Group 2 received this standard treatment as well as 10 mg/day montelukast sodium (Zespira ® 10 mg tablet) in addition to standard treatment, while patients in Group 3 received standard treatment and 20 mg/day montelukast sodium (Zespira ® 10 mg tablet) once daily.

Pulmonary function tests were performed in a negative-pressure room by a technician wearing protective equipment to prevent transmission. Before testing, patients were instructed to abstain from smoking (24 h), alcohol (4 h), strenuous exercise (30 min), and heavy meals (2 h). The patients' age, height, and weight were recorded. Tests were performed with the patients lightly dressed and BTPS (body temperature, pressure, water vapor saturated) correction was performed according to room air and barometric pressure. The technician explained the maneuver to the patients and three acceptable spirograms were obtained. Tests that met the 2019 ATS/ERS reproducibility and acceptability criteria for pulmonary function tests were included in the study. 6 The lower limits of the normal range determined for the healthy population according to the criteria specified in the same report were also calculated and presented by the spirometry device. All spirometry was performed by the same technician using a Plusmed MIR Spirolab III device. 

The comparison of the patients' laboratory parameters at admission is shown in Table 1 . There was no statistically significant difference between the groups in any laboratory parameter at admission. The comparison of laboratory parameters on Day 5 of treatment is shown in Table 2 . On Day 5, Groups 2 and 3 had significantly lower lactate dehydrogenase (LDH), fibrinogen, D-dimer, CRP, and procalcitonin levels compared with Group 1 (p = 0.04, 0.002, 0.05, 0.03, and 0.04, respectively). In the comparison between Groups 2 and 3, only fibrinogen was significantly lower in Group 3 (p = 0.02). Table 3 In addition, SARS-CoV-2 is known to enter cells by binding to human ACE2, an angiotensin-converting enzyme (ACE) receptor, leading to severe pneumonia and thus increased mortality rates during infection. 14 The cough that may develop with ACE inhibition is caused by bradykinin elevation and its bronchoconstrictor effect, whereas the selective LTD4 antagonist montelukast has an inhibitory effect on bradykinin-induced airway hypersensitivity. 15 Montelukast has been used in asthma patients for many years due to both its anti-inflammatory and bronchodilatory properties. Due to its anti-inflammatory effect on NF-κB, its use has been found to have a neuroprotective effect in pregnant women with Zika virus. 16, 17 In addition, in pediatric studies, positive results in exacerbations, cough, and disease remission were observed in children who developed bronchiolitis due to respiratory syncytial virus. 18 In our study, we detected no significant differences between the groups in laboratory and pulmonary function parameters on the day of admission, whereas LDH, fibrinogen, D-dimer, CRP, and procalcitonin levels on Day 5 of treatment were significantly lower in patients who received montelukast compared with those who did not. This may be due to the anti-inflammatory effect of montelukast sodium. In addition, the higher dose of montelukast only T A B L E 2 Comparison of laboratory parameters on Day 5 of treatment between the groups Group 1 (n = 60), mean ± SD Group 2 (n = 60), mean ± SD Group 3 (n = 60), mean ± SD p T A B L E 3 Regression analysis of laboratory and pulmonary function parameters in Group 2 (10 mg montelukast) and Group 3 (20 mg montelukast) activity. Our logistic regression analysis between 10 and 20 mg/day montelukast sodium groups showed that patients who received 20 mg montelukast had higher PEF 25-75 , which more clearly reflects the situation in the small and middle airways, and a greater decrease in fibrinogen levels. In a previous study, we observed that fibrinogen was a better indicator of the condition of the airways than other proinflammatory cytokines. When our current findings are evaluated in correlation with our previous study, we conclude that high-dose montelukast has better bronchodilator activity and that fibrinogen may be a useful guide in this respect. In the evaluation of hospital length of stay, MAS, and respiratory failure between the groups, we observed a lower frequency of MAS and respiratory failure and shorter hospital stays in both groups using montelukast, consistent with the previous data.

The main limitation of this study is the absence of long-term data for the patients in our study groups and our inability to demonstrate the effectiveness of their treatments on laboratory parameters and pulmonary function tests in the longer term.

However, we intend to also present the long-term follow-up of the patients in a later report. The limited number of patients was another limitation. When we started this study, a new SARS-CoV-2 variant still in the genetic sequencing stage emerged in place of the delta variant, which had been dominant in our region until that time. As different variants may have different effects on laboratory parameters and pulmonary function tests, we included only patients with the delta variant in our study, which limited our patient sample.

In conclusion, montelukast is known to have both antiinflammatory and bronchodilatory activity and is reported to be safe even at high doses. Its use as an adjunct therapy may prevent the development of MAS in COVID-19 patients due to its antiinflammatory effects, while its bronchodilator effect at high doses may help minimize respiratory failure in these patients and reduce their length of hospital stay.

COVID-19 pathophysiology: a review

Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome

Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19?

Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement

A literature review of the economics of COVID-19

The clinical course and its correlated immune status in COVID-19 pneumonia

In the eye of the COVID-19 cytokine storm

NF-κB pathway as a potential target for treatment of critical stage COVID-19 patients

Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms

Inflammation, cancer and oxidative lipoxygenase activity are intimately linked

Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose-and time-dependently protects against focal cerebral ischemia in mice

Interaction of SARS-CoV-2 and other coronavirus with ACE (angiotensin-converting enzyme)−2 as their main receptor: therapeutic implications

As a potential treatment of COVID-19: montelukast

Zika virus-encoded NS2A and NS4A strongly downregulate NF-κB promoter activity

Montelukast, an anti-asthmatic drug, inhibits zika virus infection by disrupting viral integrity

A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis

The authors declare that there are no conflict of interests. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

http://orcid.org/0000-0002-6048-1462Ferhan Kerget http://orcid.org/0000-0002-5160-4854Murat Aydın https://orcid.org/0000-0002-0167-0802Ömer Karaşahin https://orcid.org/0000-0002-4245-1534